Robin Filshie

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry Iland, Ken Bradstock, Shane G. Supple et al. · Blood · 2012 · 340 citations · Full text

Medicine, Hematology, Oncology +15

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

David M. Ross, Susan Branford, John F. Seymour et al. · Leukemia · 2010 · 267 citations

Medicine, Molecular Biology, Oncology +15

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

S Kamel, Linda W. Horton, Loïc Ysebaert et al. · Leukemia · 2014 · 227 citations

Medicine, Hematology, Pharmacotherapy +11

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Timothy P. Hughes, Susan Branford, Deborah L. White et al. · Blood · 2008 · 177 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +10